Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies
MedComm · 2026-06 · 7 (6)
DOI: 10.1002/mco2.70771 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 18.05.2026. Verfasst von Qintao Ge und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Shanghai Key Laboratory of Clinical Geriatric Medicine Shanghai China. Die Arbeit nennt 322 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting crucial coinhibitory pathways. Pathways involving PD‐1/PD‐L1 and CTLA‐4 are essential for immune homeostasis but are frequently exploited by tumors to evade immune surveillance. ICIs block these interactions, unleashing a potent antitumor immune response. However, broad clinical efficacy is limited by low response rates, immune‐related adverse events, and the pervasive challenge of primary or acquired resistance. This review summarizes the fundamental molecular mechanisms of key checkpoints (PD‐1/PD‐L1, CTLA‐4, TIM‐3) and highlights recent clinical progress in ICI monotherapies and combination strategies. We systematically explore multifaceted mechanisms of resistance, encompassing both tumor‐intrinsic and extrinsic factors. Furthermore, we outline novel therapeutic approaches being designed to overcome this resistance. Finally, we discuss promising predictive biomarkers and precision immuno‐oncology strategies. This review provides a critical framework for navigating the current landscape and offers a rationale to guide the future development of effective combination therapies to improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Shanghai Key Laboratory of Clinical Geriatric Medicine Shanghai China.
- Department of Urology, Fudan University Shanghai Cancer Center, Fudan University Shanghai China.
- Department of Oncology Shanghai Medical College Fudan University Shanghai China.
- Shanghai Genitourinary Cancer Institute Shanghai China.
- West China Medical Center of Sichuan University Chengdu Sichuan China.
ORCID-Profile: Wenhao Xu
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Ge, Q., Yu, L., Lu, J., Anwaier, A., Xiao, X., Chen, Y., Ye, D., Zhang, H., Xu, W., & Dai, W. (2026). Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies. MedComm, 7(6). https://doi.org/10.1002/mco2.70771
Vancouver
Ge Q, Yu L, Lu J, Anwaier A, Xiao X, Chen Y, et al. Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies. MedComm. 2026;7(6). doi:10.1002/mco2.70771
BibTeX
@article{Ge2026,
author = {Ge, Qintao and Yu, Liu and Lu, Jiahe and Anwaier, Aihetaimujiang and Xiao, Xiyue and Chen, Yonghao and Ye, Dingwei and Zhang, Hailiang and Xu, Wenhao and Dai, Wenbin},
title = {Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies},
journal = {MedComm},
year = {2026},
volume = {7},
number = {6},
doi = {10.1002/mco2.70771}
}
EUVIMED